Sanofi US has introduced an authorised generic version of Eloxatin (oxaliplatin injection), a platinum-based drug used in combination with infusional 5-fluorouracil / leucovorin.
Launched through Sanofi’s generics division, Winthrop US, the generic drug formulation is the same as the original drug, for which it holds the patent.
The drug is indicated to treat colorectal cancer, or it can be used as adjuvant treatment of stage three colon cancer in patients who have undergone complete resection of the primary tumour.
Sanofi North America chief medical officer Dr Charles Hugh-Jones said: "We are committed to broadening access to our medicines and providing more affordable treatment options for patients.
"The availability of an authorised generic version of Eloxatin is welcomed news for patients and physicians alike."
The original Eloxatin is recommended for administration in combination with 5-fluorouracil / leucovorin for every two weeks. The generic version is available in 50mg and 100mg single-use vials.
The treatment is recommended for use until disease progression or unacceptable toxicity for advanced disease, while the dosage is recommended for a total of six months (12 cycles) for adjuvant use.
The Centers for Disease Control and Prevention (CDC) said: "Of cancers that affect both men and women, colorectal cancer is the second leading cancer killer in the US."
Sanofi has seven growth platforms, including diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Image: OXALIplantin 100mg. Photo: courtesy of PRNewswire/Sanofi.